RIPK1 Inhibitor
Immunological Diseases
PreclinicalIn collaboration with Eli Lilly
Key Facts
Indication
Immunological Diseases
Phase
Preclinical
Status
In collaboration with Eli Lilly
Company
About Rigel Pharmaceuticals
Rigel Pharmaceuticals is a commercial-stage biotech with a strategic focus on hematology and oncology, building a portfolio of approved and investigational therapies. The company has successfully brought multiple products to market, including TAVALISSE for ITP and REZLIDHIA for AML, and is advancing a pipeline through both internal R&D and strategic collaborations, such as its partnership with Eli Lilly on a RIPK1 inhibitor. Headquartered in South San Francisco, Rigel operates as a public company (NASDAQ: RIGL) and is led by a seasoned management team with deep experience in biopharma development and commercialization.
View full company profile